LEUKEMIA UPDATE: The varieties and complexity of leukemia and other "liquid tumours," as well as the varying courses in each patient pose challenges for the development and use of new therapies. Progress in addressing some of those challenges was the subject of much research presented last month in San Diego at the annual meeting of the American Society of Hematology (ASH).
LEUKEMIA UPDATE: The varieties and complexity of leukemia and other “liquid tumours,” as well as the varying courses in each patient pose challenges for the development and use of new therapies. Progress in addressing some of those challenges was the subject of much research presented last month in San Diego at the annual meeting of the American Society of Hematology (ASH). Among the highlights were a newly identified gene that may guide treatment of acute lymphoblastic leukemia in children, and increasing experience with imatinib, the breakthrough drug of two years ago. Clinical editor Terry Murray files these stories.
[Editor: The preceding article was not written by A4M/WHN]
